Cargando…
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780306/ https://www.ncbi.nlm.nih.gov/pubmed/35057796 http://dx.doi.org/10.1186/s12916-021-02213-z |
_version_ | 1784637805792591872 |
---|---|
author | Mączyńska, Justyna Raes, Florian Da Pieve, Chiara Turnock, Stephen Boult, Jessica K. R. Hoebart, Julia Niedbala, Marcin Robinson, Simon P. Harrington, Kevin J. Kaspera, Wojciech Kramer-Marek, Gabriela |
author_facet | Mączyńska, Justyna Raes, Florian Da Pieve, Chiara Turnock, Stephen Boult, Jessica K. R. Hoebart, Julia Niedbala, Marcin Robinson, Simon P. Harrington, Kevin J. Kaspera, Wojciech Kramer-Marek, Gabriela |
author_sort | Mączyńska, Justyna |
collection | PubMed |
description | BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immunologically cold GBM microenvironment could improve patients’ outcomes. Herein, we report that targeted photoimmunotherapy (PIT) not only helps to define tumour location and margins but additionally promotes activation of anti-GBM T cell response. METHODS: EGFR-specific affibody molecule (Z(EGFR:03115)) was conjugated to IR700. The response to Z(EGFR:03115)-IR700-PIT was investigated in vitro and in vivo in GBM cell lines and xenograft model. To determine the tumour-specific immune response post-PIT, a syngeneic GBM model was used. RESULTS: In vitro findings confirmed the ability of Z(EGFR:03115)-IR700 to produce reactive oxygen species upon light irradiation. Z(EGFR:03115)-IR700-PIT promoted immunogenic cell death that triggered the release of damage-associated molecular patterns (DAMPs) (calreticulin, ATP, HSP70/90, and HMGB1) into the medium, leading to dendritic cell maturation. In vivo, therapeutic response to light-activated conjugate was observed in brain tumours as early as 1 h post-irradiation. Staining of the brain sections showed reduced cell proliferation, tumour necrosis, and microhaemorrhage within PIT-treated tumours that corroborated MRI T(2)*w acquisitions. Additionally, enhanced immunological response post-PIT resulted in the attraction and activation of T cells in mice bearing murine GBM brain tumours. CONCLUSIONS: Our data underline the potential of Z(EGFR:03115)-IR700 to accurately visualise EGFR-positive brain tumours and to destroy tumour cells post-conjugate irradiation turning an immunosuppressive tumour environment into an immune-vulnerable one. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02213-z. |
format | Online Article Text |
id | pubmed-8780306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87803062022-01-21 Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy Mączyńska, Justyna Raes, Florian Da Pieve, Chiara Turnock, Stephen Boult, Jessica K. R. Hoebart, Julia Niedbala, Marcin Robinson, Simon P. Harrington, Kevin J. Kaspera, Wojciech Kramer-Marek, Gabriela BMC Med Research Article BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immunologically cold GBM microenvironment could improve patients’ outcomes. Herein, we report that targeted photoimmunotherapy (PIT) not only helps to define tumour location and margins but additionally promotes activation of anti-GBM T cell response. METHODS: EGFR-specific affibody molecule (Z(EGFR:03115)) was conjugated to IR700. The response to Z(EGFR:03115)-IR700-PIT was investigated in vitro and in vivo in GBM cell lines and xenograft model. To determine the tumour-specific immune response post-PIT, a syngeneic GBM model was used. RESULTS: In vitro findings confirmed the ability of Z(EGFR:03115)-IR700 to produce reactive oxygen species upon light irradiation. Z(EGFR:03115)-IR700-PIT promoted immunogenic cell death that triggered the release of damage-associated molecular patterns (DAMPs) (calreticulin, ATP, HSP70/90, and HMGB1) into the medium, leading to dendritic cell maturation. In vivo, therapeutic response to light-activated conjugate was observed in brain tumours as early as 1 h post-irradiation. Staining of the brain sections showed reduced cell proliferation, tumour necrosis, and microhaemorrhage within PIT-treated tumours that corroborated MRI T(2)*w acquisitions. Additionally, enhanced immunological response post-PIT resulted in the attraction and activation of T cells in mice bearing murine GBM brain tumours. CONCLUSIONS: Our data underline the potential of Z(EGFR:03115)-IR700 to accurately visualise EGFR-positive brain tumours and to destroy tumour cells post-conjugate irradiation turning an immunosuppressive tumour environment into an immune-vulnerable one. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02213-z. BioMed Central 2022-01-21 /pmc/articles/PMC8780306/ /pubmed/35057796 http://dx.doi.org/10.1186/s12916-021-02213-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Mączyńska, Justyna Raes, Florian Da Pieve, Chiara Turnock, Stephen Boult, Jessica K. R. Hoebart, Julia Niedbala, Marcin Robinson, Simon P. Harrington, Kevin J. Kaspera, Wojciech Kramer-Marek, Gabriela Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy |
title | Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy |
title_full | Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy |
title_fullStr | Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy |
title_full_unstemmed | Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy |
title_short | Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy |
title_sort | triggering anti-gbm immune response with egfr-mediated photoimmunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780306/ https://www.ncbi.nlm.nih.gov/pubmed/35057796 http://dx.doi.org/10.1186/s12916-021-02213-z |
work_keys_str_mv | AT maczynskajustyna triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT raesflorian triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT dapievechiara triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT turnockstephen triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT boultjessicakr triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT hoebartjulia triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT niedbalamarcin triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT robinsonsimonp triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT harringtonkevinj triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT kasperawojciech triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy AT kramermarekgabriela triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy |